TSE:2395Life Sciences
Shin Nippon Biomedical Laboratories Q3 Net Margin Compression Tests Bullish Growth Narrative
Q3 2026 Earnings Snapshot and What Comes Next for the Story
Shin Nippon Biomedical Laboratories (TSE:2395) has posted Q3 2026 revenue of ¥6,429 million and net income of ¥1,209 million, with EPS at ¥29.04. This sets a clear benchmark for how the rest of the year is shaping up. The company has seen quarterly revenue move from ¥9,726.89 million in Q3 2025 to ¥10,177.63 million in Q4 2025, then settle at ¥6,477.68 million in Q1 2026 and ¥8,288.32 million in Q2 2026. EPS has shifted from ¥45.03...